
Opinion|Videos|April 7, 2025
18-Month Retrospective Claims Analysis Study Information on Ruxolitinib
Author(s)Gary M. Owens, MD , Lawrence Eichenfield, MD
Panelists discuss how the 18-month retrospective claims analysis of ruxolitinib revealed sustained efficacy in atopic dermatitis management, with significant reductions in disease flares, healthcare utilization, and concomitant medication use compared to conventional therapies, while maintaining a consistent safety profile across diverse patient populations and disease severities.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Daraxonrasib trial exceeds expectations after decades of disappointment in pancreatic cancer drug development
2
Alyana Samai, M.P.H. | 2026 MHE Emerging Leaders in Healthcare
3
Brukinsa provides long-term disease control in chronic lymphocytic leukemia
4
FDA approves Differin Epiduo Acne Gel for over-the-counter use
5

























